R1	Has_value Arg1:T2 Arg2:T3	
R2	Has_temporal Arg1:T7 Arg2:T8	
R3	AND Arg1:T7 Arg2:T6	
*	OR T12 T13
R4	AND Arg1:T11 Arg2:T12	
R5	Has_temporal Arg1:T15 Arg2:T16	
*	OR T17 T18
R6	Has_qualifier Arg1:T19 Arg2:T17	
R7	Subsumes Arg1:T23 Arg2:T24	
R8	Subsumes Arg1:T21 Arg2:T22	
*	OR T11 T23 T19 T15 T27 T21
*	OR T25 T26
R9	Has_value Arg1:T28 Arg2:T29	
R10	Subsumes Arg1:T25 Arg2:T28	
R11	Has_qualifier Arg1:T27 Arg2:T25	
R12	AND Arg1:T9 Arg2:T10	
R13	Subsumes Arg1:T9 Arg2:T11	
*	OR T34 T33
R14	Has_temporal Arg1:T34 Arg2:T35	
R15	Has_qualifier Arg1:T36 Arg2:T34	
R16	Has_value Arg1:T41 Arg2:T42	
*	OR T38 T39 T40
R17	AND Arg1:T38 Arg2:T36	
*	OR T38 T41
R18	Has_temporal Arg1:T44 Arg2:T45	
*	OR T48 T47
R19	Has_temporal Arg1:T46 Arg2:T48	
R20	Has_negation Arg1:T52 Arg2:T53	
*	OR T50 T51
R21	AND Arg1:T51 Arg2:T52	
*	OR T56 T57
R22	Has_qualifier Arg1:T55 Arg2:T56	
R23	Has_value Arg1:T54 Arg2:T55	
R24	Has_multiplier Arg1:T59 Arg2:T60	
*	OR T61 T63 T62 T64
R25	Has_temporal Arg1:T61 Arg2:T65	
R26	Has_temporal Arg1:T67 Arg2:T68	
R27	Has_temporal Arg1:T67 Arg2:T69	
*	OR T59 T61 T67
R28	Has_temporal Arg1:T70 Arg2:T71	
T1	Pregnancy_considerations 0 100	Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study
T2	Person 111 115	aged
T3	Value 116 132	<18 years of age
T4	Non-query-able 134 176	Patients who cannot give informed consent,
T5	Pregnancy_considerations 178 252	Pregnant patients or those who are breastfeeding will be deemed ineligible
T6	Drug 280 294	anti-TNF agent
T7	Procedure 261 270	treatment
T8	Temporal 255 260	Prior
T9	Condition 296 313	Contra-indication
T10	Drug 324 327	GLM
T11	Condition 329 345	Hypersensitivity
T12	Drug 353 369	active substance
T13	Drug 387 397	excipients
T15	Condition 406 423	tuberculosis (TB)
T16	Temporal 399 405	Active
T17	Qualifier 425 430	acute
T18	Qualifier 434 441	chronic
T19	Condition 442 463	Hepatitis B infection
T21	Condition 473 490	severe infections
T22	Condition 499 505	sepsis
T23	Condition 513 537	opportunistic infections
T24	Condition 548 561	HIV infection
T25	Qualifier 563 571	Moderate
T26	Qualifier 575 581	severe
T27	Condition 582 595	heart failure
T28	Measurement 597 601	NYHA
T29	Value 602 614	class III/IV
T33	Qualifier 672 678	latent
T34	Qualifier 662 668	active
T35	Temporal 654 661	current
T36	Condition 679 681	TB
T38	Temporal 687 702	medical history
T39	Procedure 704 724	physical examination
T40	Procedure 732 748	chest radiograph
T41	Measurement 762 843	Mycobacterium tuberculosis antigen-specific interferon-gamma release assay (IGRA)
T42	Value 753 761	positive
T44	Procedure 922 946	gastrointestinal surgery
T45	Temporal 947 979	within 2 months before screening
T46	Procedure 898 907	colectomy
T47	Mood 879 896	imminent risk for
T48	Temporal 861 871	history of
T50	Condition 993 1018	colonic mucosal dysplasia
T51	Condition 1022 1048	adenomatous colonic polyps
T52	Procedure 1063 1070	removed
T53	Negation 1059 1062	not
T54	Procedure 1082 1093	stool study
T55	Value 1094 1102	positive
T56	Qualifier 1107 1124	enteric pathogens
T57	Qualifier 1128 1155	Clostridium difficile toxin
T59	Drug 1158 1178	Oral corticosteroids
T60	Multiplier 1189 1206;1225 1232	>40 mg prednisone per day
T61	Drug 1245 1257	cyclosporine
T62	Drug 1259 1269	tacrolimus
T63	Drug 1271 1280	sirolimus
T64	Drug 1285 1306	mycophenolate mofetil
T65	Temporal 1307 1360	within 8 weeks before the first study agent injection
T67	Drug 1375 1396	investigational agent
T68	Temporal 1397 1416	within 5 half-lives
T69	Temporal 1431 1469	before the first study agent injection
T70	Drug 1502 1519	live vaccinations
T71	Temporal 1520 1553	within 4 weeks prior to enrolment
